There are 300 million cases of malaria each year worldwide, causing one million deaths. Around 90% of these deaths occur in Africa, mostly in young children. One of the greatest challenges facing Africa in the fight against malaria is drug resistance; resistance to chloroquine (CQ), the cheapest and most widely used antimalarial, is common throughout Africa, and resistance to sulfadoxine-pyrimethamine (SP), the first-developed and least expensive alternative to CQ, is also increasing. These trends have forced many countries to change their treatment policies and use more expensive drugs, including drug combinations that will hopefully slow the development of resistance and minimize transmission of resistant parasites.
In this month's premier open-access journal PLoS Medicine Colin Sutherland and colleagues from the London School of Hygiene and Tropical Medicine report the results of a randomized, controlled trial of 497 children in Uganda treated with one of two leading combination therapies. One regimen was an artemisinin-based combination consisting of artemether and lumefantrine (co-artemether, trade names CoArtem and Riamet). The other was a combination of CQ and SP - currently under consideration in several African countries, largely due to its low cost. Altogether, the six-dose regimen of co-artemether was highly effective at reducing whether and how long children had gametocytes - the infective form of the malarial parasite - in their blood. The numbers of gametocytes carried and how able they were to infect mosquitoes 7 days later was also reduced by the six dose regimen.
Although the results are promising, some patients may have difficulty taking a six-dose regimen, and as it also needs oily food for adequate absorption there might be inadequate drug levels in the blood of many treated individuals. The authors conclude that although co-artemether as a first-line treatment is not likely to reduce overall transmission of Plasmodi
'"/>
Contact: Paul Ocampo
pocampo@plos.org
415-624-1224
Public Library of Science
25-Apr-2005
Page: 1 2 Related medicine news :1.
Reducing tobacco use in US2.
Reducing cardiovascular disease risk factors when discontinuing hormone replacement therapy3.
Reducing side effects of painkillers4.
Reducing contrast material injection in elderly patients can lower cost of exam and risks5.
Sudden infant death syndrome: Reducing the risk6.
Reducing dose errors for children in cardiac arrest7.
Reducing the damage caused by cardiac arrest8.
Reducing fine particulate air pollution cuts mortality risk9.
Reducing oral health disparities: Achieving healthy people 2010 objectives10.
Reducing teens intake of sugary drinks11.
Reducing barriers to exercise can save womens lives